Effect Observation of Biqui Capsule Combined with Hydroxychloroquine in the Treatment of Rheumatoid Arthritis

doi:10.16458/j.cnki.1007-0893.2025.15.011

Abstract：Objective: To investigate the effect of Biqui capsule combined with hydroxychloroquine in the treatment of rheumatoid arthritis (RA). Methods: A total of 60 RA patients admitted to the First People's Hospital of Zhumadian City from February 2022 to December 2024 were prospectively enrolled as study subjects. They were randomly divided into an observation group and a control group using a random number table method, with 30 cases in each group. All patients received basic treatment, while the control group was additionally treated with hydroxychloroquine monotherapy, and the observation group received Biqui capsule therapy on top of the control group's treatment. The clinical efficacy, disease activity degree, serum inflammatory factor levels, and incidence of adverse reactions were compared between the two groups before and after treatment. Results: The total effective rate of the observation group was higher than that of the control group, with a statistically significant difference (P < 0.05). After treatment, the moderate activity rate of the observation group was lower than that of the control group, while the remission rate and low activity rate were higher, with statistically significant differences (P < 0.05). After treatment, the serum levels of C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) in the observation group were lower than those in the control group, with statistically significant differences (P < 0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Treatment with Biqui capsule combined with hydroxychloroquine in RA patients can improve treatment effectiveness, alleviate disease activity, inhibit inflammatory responses, and does not increase adverse reactions.